This is supported by the synergism between TKIs and chemotherapy, which have been proven to be successful in the treatment of other hematological malignancies, including B-cell acute lymphoid leukemia with BCR::ABL1 fusion [25,26]. The gene discussed is ABL1; the disease is hematologic disorder.